Protein kinase C (PKC) has been implicated in the control of neurotransmitter release. The AS/AGU rat, which has a nonsense mutation in PKC␥, shows symptoms of parkinsonian syndrome, including dopamine release impairments in the striatum. Here, we found that the AS/AGU rat is PKC␥-knock-out (KO) and that PKC␥-KO mice showed parkinsonian syndrome. However, the PKC␥ substrates responsible for the regulated exocytosis of dopamine in vivo have not yet been elucidated. To identify the PKC␥ substrates involved in dopamine release, we used PKC␥-KO mice and a phosphoproteome analysis. We found 10 candidate phosphoproteins that had decreased phosphorylation levels in the striatum of PKC␥-KO mice. We focused on Pak-interacting exchange factor-␤ (␤PIX), a Cdc42/Rac1 guanine nucleotide exchange factor, and found that PKC␥ directly phosphorylates ␤PIX at Ser583 and indirectly at Ser340 in cells. Furthermore, we found that PKC phosphorylated ␤PIX in vivo. Classical PKC inhibitors and ␤PIX knock-down (KD) significantly suppressed Ca 2ϩ -evoked dopamine release in PC12 cells. Wild-type ␤PIX, and not the ␤PIX mutants Ser340 Ala or Ser583 Ala, fully rescued the decreased dopamine release by ␤PIX KD. Double KD of Cdc42 and Rac1 decreased dopamine release from PC12 cells. These findings indicate that the phosphorylation of ␤PIX at Ser340 and Ser583 has pivotal roles in Ca 2ϩ -evoked dopamine release in the striatum. Therefore, we propose that PKC␥ positively modulates dopamine release through ␤2PIX phosphorylation. The PKC␥-␤PIX-Cdc42/Rac1 phosphorylation axis may provide a new therapeutic target for the treatment of parkinsonian syndrome.
Introduction
Protein kinase C (PKC) is an important kinase in the enhancement of Ca 2ϩ -triggered exocytosis (Iwasaki et al., 2000; Barclay et al., 2003) . The PKC family consists of at least 10 subtypes and is divided into the following three subfamilies: conventional PKC (cPKC), novel PKC, and atypical PKC (Nishizuka, 1988 (Nishizuka, , 1992 . Among PKCs, only cPKCs (including PKC␥, which is a neuron-specific PKC isoform; Saito and Shirai, 2002) are activated by Ca 2ϩ because they contain a C2 domain that specifically binds to Ca 2ϩ and phosphatidylserine (PS; Murray and Honig, 2002) .
The AS/AGU rat, a spontaneously occurring mutated animal that exhibits locomotor abnormalities, progressive dopaminergic (DAergic) neuronal degeneration in the substantia nigra (SN), and lower extracellular levels of dopamine (DA) in the striatum, has been used as a valuable model for parkinsonian syndrome . It is noteworthy that a mutation in PKC␥ that leads to the early termination at the C2 domain without possessing the catalytic domain causes parkinsonian syndrome in AS/ AGU rats (Craig et al., 2001) . The mutation in AS/AGU rats should result in the kinase-dead form of PKC␥, but it is still unclear how the mutation causes parkinsonian symptoms.
PKC has been shown to modify exocytosis in at least three steps: (1) increased vesicle recruitment into readily releasable pools (Gillis et al., 1996; Stevens and Sullivan, 1998) , (2) acceleration of fusion pore expansion (Scepek et al., 1998) , and (3) changes in the kinetics of exocytosis (Graham et al., 2002) . However, only the functional consequences of the phosphorylation of SNAP25 (Iwasaki et al., 2000) , synaptotagmin I (Hilfiker et al., 1999) , and Munc18 (Barclay et al., 2003) by PKC have been established on exocytosis in vivo. Furthermore, no attempts have been made to achieve a comprehensive understanding of DA exocytosis through an identification of PKC␥ substrates. Therefore, we attempted to identify the PKC substrates involved in exocytosis to reveal the mechanisms of regulated exocytosis.
Pak-interacting exchange factor-␤ (␤PIX) is a Rho guanine nucleotide exchange factor (GEF) that specifically activates Rac1 and Cdc42 (Shin et al., 2002; Shin et al., 2004; Chahdi et al., 2005; Feng et al., 2006; Shin et al., 2006; ten Klooster et al., 2006; Chahdi and Sorokin, 2008) . ␤PIX has been reported to be an essential element of the exocytotic machinery in neuroendocrine cells (Audebert et al., 2004; Momboisse et al., 2009 ). To date, there have been several studies on ␤PIX phosphorylation (Shin et al., 2002; Chahdi et al., 2005; Shin et al., 2006; Mayhew et al., 2007) , but there have been no reports of the involvement of ␤PIX phosphorylation in DA release.
In the present study, we found that the AS/AGU rat is indeed a PKC␥-knock-out (KO) animal, and our phosphoproteome analysis using PKC␥ KO mice found 10 candidates in the striatum that are phosphorylated by PKC␥. Among the 10 candidates, we demonstrated that PKC␥ activated DA release through the phosphorylation of ␤PIX.
Materials and Methods
Antibodies. The anti-GFP antibody (Ab) and the anti-vesicular monoamine transporter 2 (VMAT2) Ab recognizing the C-terminal of mouse VMAT2 were prepared in house. The anti-PKC␥ (C2-domain) monoclonal Abs specifically recognizing C2-domain of PKC␥ have been described previously (Kose et al., 1990) . The following Abs were purchased: anti-FLAG from Sigma-Aldrich (catalog #P2983 RRID:AB_439685); anti-␤PIX (SH3 domain) from Millipore; anti-␤-actin (catalog #ab66338 RRID:AB_2289239) and anti-PKC␥ (N-terminal) specifically recognizing N-terminal of PKC␥ from Abcam; anti-glutathione S-transferase (GST) (catalog #sc-33613 RRID:AB_647588), anti-PKC␣ (catalog #sc-208 RRID:AB_2168668), anti-PKC␤1 (catalog #sc-209 RRID:AB_2168968), anti-PKC␤2 (catalog #sc-210 RRID:AB_2252825), and anti-PKC␥ (catalog #sc-211 RRID:AB_632234) from Santa Cruz Biotechnology; and anti-serPKC motif (catalog #2261S RRID: AB_330310), anti-␤PIX (catalog #4515S RRID:AB_2274365) for immunoprecipitation (IP), and anti-postsynaptic density-95 (PSD95; catalog #2507S RRID:AB_10695259) from Cell Signaling Technology.
Production of Abs. The production of anti-phospho Abs was performed as described previously (Matsubara et al., 2012) . For the preparation of anti-phospho-Thr76 (pT76), anti-phospho-Ser340 (pS340), and antiphospho-Ser583 (pS583) ␤PIX Abs, oligopeptides corresponding to the amino acids of human ␤PIX containing pT76 [VSPKSG(pT)LKSPP], pS340 [SASPRM(pS)GFIYQ], and pS583 [SLGRRS(pS)LSRLE] were used as antigens, respectively. After the fifth boost, serum was collected and purified with an affinity column and the non-phospho-antigen peptide. The anti-␤2PIX Ab was obtained by eluting the IgG from those that were bound to the nonphospho-Ser583 peptide column.
Animals. The AS/AGU rats were provided by R.W. . The PKC␥-Cre knockin (KI) mouse was provided by Z.F. Chen (Ding et al., 2005) . After the sixth backcross, homozygous littermates obtained by crossing the heterozygous PKC␥-Cre KI mouse were used as the PKC␥ KO and wild-type (WT) mice in the studies. All animal studies were approved by the Institutional Animal Care and Use Committee and conducted according to the Kobe University Animal Experimentation Regulations.
Sample preparation and Western blot analysis. The brains from AS/ AGU rats and mice were homogenized and the concentrations of the proteins were measured with a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific). SDS-PAGE and immunoblot analyses were performed as described previously (Adachi et al., 2005) .
Preparation of P2 synaptosomal fraction. Adult male mouse brains were collected and homogenized in ice-cold 0.32 M sucrose solution containing 1 mM phenylmethylsulfonyl fluoride, 20 g/ml leupeptin, and a phosphatase-inhibitor cocktail (Nacalai Tesque). The total homogenate was subjected to centrifugation at 800 ϫ g for 12 min at 4°C to remove the nuclei and the supernatant, which we defined as the total fraction, was further centrifuged at high speed at 22,000 ϫ g for 20 min at 4°C. The pellet was used as the P2 synaptosomal fraction. To determine the efficiency of the P2 synaptosomal extraction process, we compared the amount of VMAT2 and PSD95 proteins between the total fraction and P2 synaptosomal fraction in the same amount of protein (50 g), which was calculated using the BCA protein assay kit.
In vivo microdialysis. In vivo microdialysis was performed with male mice essentially as described previously (Koda et al., 2010; Ago et al., 2013) . In brief, mice were anesthetized by injection of sodium pentobarbital (40 mg/kg, i.p.), and a guide cannula (one site per animal) for a dialysis probe (Eicom) was implanted stereotaxically in the dorsal striatum (anterior 0.1 mm, lateral 1.8 mm, ventral 2.2 mm relative to the bregma and skull; Franklin and Paxinos, 1997). The cannula was cemented in place with dental acrylic and the animals were maintained warm and allowed to recover from anesthesia. The active probe membrane was 1 mm in length. Two days after the surgery, the probe was perfused with Ringer's solution (147.2 mM NaCl, 4.0 mM KCl, and 2.2 mM CaCl 2 , pH 6.0; Fuso Pharmaceutical Industries) at a constant flow rate of 1 l/min. To prepare the Ringer's solution containing 100 mM K ϩ , an identical amount of sodium was replaced for maintaining isoosmolarity. Experiments were initiated after a stabilization period of 3 h. Microdialysis samples (20 l) were collected every 20 min and were assayed for DA by high-performance liquid chromatography (HPLC) with electrochemical detection. No-net-flux microdialysis experiments were conducted in a PKC␥ KO and WT mice as described previously (Justice, 1993; Chefer et al., 2005; Hewett et al., 2010) . Three different concentrations of DA in Ringer's solution (C in of 0, 5 and 20 nM DA) were perfused through the probe and DA in the perfusates (C out ) was measured in the fifth fraction following 4 fractions (equilibration period) at each applied DA concentration. A slope was calculated for the linear regression for DA applied (C in ) and the difference between dopamine applied and DA measured (C in Ϫ C out ). The slope (extraction fraction) is an indirect measure of dopamine transporter (DAT) dynamics in vivo to remove extracellular DA.
Measurement of DA and DA metabolite levels in striatum. The concentrations of DA were quantified by HPLC with an electrochemical detector (ECD-100; Eicom; Kawasaki et al., 2006; Kawasaki et al., 2007) . Tissue samples were homogenized in 0.2 M perchloric acid containing 100 M EDTA and isoproterenol as an internal standard. The homogenate was centrifuged at 15,000 ϫ g for 15 min at 0°C. The supernatant was filtered through a 0.22 m membrane filter (Millipore), and then a 10 l aliquot of the sample was injected onto the HPLC column every 30 min for the DA assay. An Eicompak SC-5ODS column (3.0 mm i.d. ϫ 150 mm; Eicom) was used, and the potential of the graphite electrode (Eicom) was set to ϩ750 mV against an Ag/AgCl reference electrode. The mobile phase contained 0.1 M sodium acetate/0.1 M citrate buffer, pH 3.5, 190 mg/L octanesulfonic acid, 5 mg/L EDTA, and 17% (v/v) methanol. Data were calculated by analyzing the peak area of the external standard of dopamine hydrochloride (Sigma-Aldrich).
Cell culture. COS7 and HEK293 cells were cultured in DMEM and Eagle's minimum essential medium (Nacalai Tesque), respectively, which were supplemented with 10% fetal bovine serum, penicillin (100 units/ml), and streptomycin (100 g/ml). Nonessential amino acids (100 M) were added for HEK293 cells. PC12 cells were cultured in DMEM containing 10% fetal bovine serum and 5% horse serum. All cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 .
Construction of plasmids. WT PKC␥ was cloned into pcDNA3.1 (Life Technologies) and the subdomains of PKC␥ were cloned into pcDNA3.1 with GFP, as described previously (Seki et al., 2005) . Human ␤PIX was provided by the RIKEN BioResource Center through the National BioResource Project of MEXT in Ibaraki, Japan (Ota et al., 2004) . For the construction of plasmids encoding full-length ␤2PIX that was fused with 3xFLAG at the N terminal, ␤2PIX with a NotI/BamHI site that was produced by PCR was cloned into a 3xpFLAG-CMV10 vector (SigmaAldrich). Because the target sequence for rat ␤PIX knock-down (KD; sh369) was located in the coding region of ␤PIX, sh369-resistant ␤2PIX in the 3xpFLAG-CMV10 vector was made by placing 6-base silent Figure 1 . The PKC␥ KO model exhibits symptoms of parkinsonian syndrome. A, Schematic illustrations of the PKC␥ protein and AS/AGU mutations. The truncated PKC␥ polypeptide terminates within the C2 domain. B, Recombinant truncated PKC␥ (1-280 aa), which was transfected in COS-7 cells, the AS rat brain lysate, and the AS/AGU rat brain lysate, was detected by immunoblot analysis with an anti-PKC␥ (C2-domain) monoclonal antibody and anti-PKC␥ (N terminal) antibody, respectively. C, The PKC␥ KO was confirmed by immunoblot analysis of the whole brain of the AS/AGU rats and PKC␥ KO mice. Arrowheads are recombinant PKC␥-GFP and PKC␥ (1-280aa)-GFP, which were used as positive controls. D, In vivo microdialysis in the striatum of the PKC␥ KO mice. A high level of K ϩ was perfused into the striatum through a dialysis probe for the time indicated by the square at 3-4 months. The results are expressed as mean Ϯ SEM (n ϭ 4 -5, interaction of the genotype and time for DA release that was stimulated by high K ϩ levels; *p Ͻ 0.05, F (8,48) ϭ 2.31, repeated two-way ANOVA). E, In vivo microdialysis for DA in the striatum of the PKC␥-KO (KO) mice that were stimulated with METH. METH (1 mg/kg) was perfused into the striatum through a dialysis probe for the time indicated by the square at 3 months (Figure legend continues.) changes within the targeting sequence (5Ј-CAaACgAGtGAaAAaTTa-3Ј) with a QuikChange Multisite-Directed Mutagenesis Kit (Agilent Technologies). For construction of plasmids encoding full-length ␤2PIX or fragments that were fused to GST, full-length ␤2PIX and the SH3 (1-92 aa), DH (93-274 aa), and PH (275-400 aa) C-terminal (401-625 aa) regions were amplified by PCR with a Not1/BamH1 site and cloned into the pGEX-6P1 vector. Substitutions of Ser or Thr to Ala or Glu at the identified phosphorylation sites (Thr76Ala, Ser215Ala, Ser340Ala or Glu, and Ser583Ala or Glu) were introduced with a QuikChange kit.
Protein expression. Protein expression was performed as described previously (Kawasaki et al., 2010) . In brief, BL21 pLys Escherichia coli and Sf9 cells were transformed with expression plasmids. E. coli and Sf9 cells were harvested and lysed. For the purification of recombinant proteins, GSTfusion proteins were purified with glutathione-Sepharose 4B resin (GE Healthcare Biosciences).
RNAi: short hairpin RNA and small interfering RNA. Double-stranded oligonucleotides were cloned into the short hairpin RNA (shRNA) expression vector, pSuper (puro; Oligoengine). The target sequence for the shRNA rat ␤PIX KD was 5Ј-GCAGACCAGCGAGAAGTTGAG-3Ј (sh369; cording nucleotides 369 -389). Because the ␤PIX shRNA sequence that we used was common to both the ␤1 and ␤2 isoforms, KDs of both ␤1 and ␤2 in PC12 cells were examined with ␤PIX SH3-and ␤2-specific antibodies. The synthesized small interfering RNA (siRNA) for rat ␤PIX was composed of a mixture of 4 oligonucleotides (si878: 5Ј-GGGAUGACAUAAAGACGUU-3Ј, si806: 5Ј-AGUGUCAAGAAGU ACGAAA-3Ј, si1115: 5Ј-GGAGCAUGAUCGAGCGCAU-3Ј, and si1153: 5Ј-CAACAGGACUUGCACGAAU-3Ј) was purchased from Thermo Fisher Scientific (SmartPool). Verified shRNA plasmids for KD of Cdc42 (sh197; 5Ј-GATTACGACCGCTGAGTTA-3Ј; Ueyama et al., 2014) and Rac1 (sh618; 5Ј-CCTTTGTACGCTTTGCTCA-3Ј; Ueyama et al., 2006) were described previously.
In vitro PKC phosphorylation assay. An in vitro PKC phosphorylation assay was performed as described previously (Kawasaki et al., 2010) . In brief, precipitated FLAG-tagged ␤2PIX proteins or purified GST-tagged ␤2PIX were incubated with 200 ng of GST-tagged PKC␥ or GST and the following buffers: 20 mM Tris, pH 7.4, 0.5 mM CaCl 2 , 10 M ATP, 0.5 mCi [␥- 32 P] ATP, 8 g/ml PS, and 0.8 g/ml (Ϯ)-1,2-didecanoylglycerol (DO) in a 50 l final volume. The samples were incubated with or without PKC inhibitors, including GF109203X (GFX), which was used as a pan PKC inhibitor, and Gö6976, which was used as a cPKC inhibitor, at 30°C for 15 min. For the calculation of the relative phosphorylation levels, the densitometries of the autoradiography were normalized with the total protein levels. The average relative phosphorylation levels of PKC␥ stimulation were defined as 1.00.
PKC phosphorylation assay in cells. A PKC phosphorylation assay in cells was performed as described previously (Kawasaki et al., 2010) but with slight modifications. In brief, HEK293 cells were transfected with WT ␤2PIX in 3xpFLAG-CMV10 with a NEPA21 electroporator (Nepa Gene). After 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulation with or without PKC inhibitors for 30 min in HEPES buffer at 37°C, the cells were collected and resuspended in homogenization buffer containing 150 mM NaCl, 10 mM ethylene glycol tetraacetic acid, 2 mM ethylenediamine tetracetic acid, 10 mM HEPES, pH 7.4, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml leupeptin, and a phosphatase-inhibitor cocktail. The precipitated proteins were separated by SDS-PAGE. The phosphorylated proteins were visualized with phospho-Abs. For the calculation of the relative phosphorylation levels, the densitometries of the immunoblots of the phospho-Abs were normalized to the total protein levels in each experiment and the averages of the relative levels of phosphorylation in more than three independent experiments are presented. The phosphorylation levels of the prestimulations were defined as 1.00.
PKC phosphorylation assay in vivo. The mice P2 synaptosomal fraction was resuspended in HEPES buffer containing 1 mM phenylmethylsulfonyl fluoride, 20 g/ml leupeptin, and a phosphatase-inhibitor mixture and used for the in vivo PKC phosphorylation assay (Wu et al., 1982) . After 2 M TPA stimulation with or without 2 M GFX for 30 min in HEPES buffer at 37°C, the P2 fraction was collected and resuspended in homogenization buffer containing 150 mM NaCl, 10 mM ethylene glycol tetraacetic acid, 2 mM ethylenediamine tetracetic acid, 10 mM HEPES, pH 7.4, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml leupeptin, and the phosphatase-inhibitor mixture. The precipitated proteins were separated by SDS-PAGE. The phosphorylated proteins were visualized with ser-PKC motif Abs.
DA release assay. DA release assays in ␤PIX KD cells were performed 96 h after transfection by NEPA21. PC12 cells were washed thrice with 500 l of incubation solution (140 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 2 mM glucose, 20 M pargyline, and 10 mM HEPES, pH 7.5) and then incubated for 60 min in 500 l of incubation solution with 3 H-DA (PerkinElmer), followed by three washes with 500 l of incubation solution. The cells were allowed to rest or were stimulated with 500 l of a high-K ϩ solution containing 100 mM KCl and 35 mM NaCl for 10 min. The supernatant was collected and the cells were harvested in 500 l of incubation solution with 2% Triton X-100. The amount of DA that was secreted into the medium and retained in the cells was measured in 500 l of samples with a scintillation counter LS-6500 (Beckman Coulter). DA secretion was expressed by the following formula:
H in cell lysate). A collagen-IV-coated six-well plate (BD Biosciences) was used for the DA release assay.
Mass spectrometry for ␤2PIX-phosphorylation site identification. Mass spectrometry for ␤2PIX-phosphorylation site identification was performed as described previously . After the in vitro PKC phosphorylation assay and electrophoresis, silver-stained bands that corresponded to GST-tagged ␤2PIX proteins were excised and destained. After reduction-alkylation reactions, the proteins in the gels were digested with porcine trypsin (sequencing grade; Promega) in 50 mM ammonium bicarbonate for 15 h at 37°C. The peptide fragments extracted from the gels were subjected to liquid chromatography/tandem mass spectrometry (LC/MS/MS) with a high-performance liquid chromatography system (Paradigm MS4; Michrom Bioresources) coupled to a linear ion trap mass spectrometer (Finnigan LTQ Orbitrap XL; Thermo Fisher Scientific). The LC/MS/MS data were interpreted with a MASCOT MS/MS ions search (Matrix Science).
Phosphoproteome analysis. Phosphoproteome analysis was performed as described previously with some modifications . Mice striata were dissolved in 50 mM Tris HCl, pH 9.0, 8 M urea, 10 mM ethylenediamine tetracetic acid, 1 mM phenylmethylsulfonyl fluoride, 20 g/ml leupeptin, and a phosphatase inhibitor mixture. After homogenization with a Dounce homogenizer (10 strokes), the resultant solution was centrifuged at 2000 ϫ g for 5 min and the supernatant was collected. The protein amounts were measured with a BCA protein assay kit. The proteins from the striatum were dried and resuspended in 50 mM Tris HCl buffer, pH 9.0, containing 8 M urea at a concentration of 10 g/l. These mixtures were subsequently reduced with dithiothreitol, alkylated with acrylamide, and digested with Lys-C endopeptidase at 37°C overnight, followed by trypsin digestion at 37°C overnight. The digested solutions were desalted and concentrated with Empore high-performance extraction disk cartridges (3M). Phosphopeptide enrichment was performed with hydroxy acid-modified metal oxide chromatography (HAMMOC; Titansphere Phos-TiO Kit; GL Sciences; Kyono et al., 2008) . For elution of the phosphopeptides, 50 l of 5% NH 3 and 5% pyrrolidine were used. The fractions were immediately acidified and desalted with SPE-C tips (GL Sciences). A Tomy CC-105 vacuum evap-4 (Figure legend continued.) (n ϭ 4, interaction of the genotype and time for DA release stimulated by METH, F (8,48) ϭ 3.37; *p Ͻ 0.01, repeated two-way ANOVA). F, No-net flux microdialysis to quantitate basal DAT activity in PKC␥ KO mice. Three different concentrations of DA in CSF (0, 5, and 20 nM DA) were perfused through the probes to determine the extracellular DA concentration and extraction fraction. Linear regression for the DA perfused and DA measured provided extraction fraction (slope) as an indirect measure of DAT activity in vivo to remove extracellular DA. Extraction fraction for WT and KO mice are shown. Data represent mean Ϯ SEM (n ϭ 4 and 5 for WT and KO mice, respectively, *p Ͻ 0.05). G, In vivo microdialysis of serotonin in the striatum of the PKC␥-KO mice that were stimulated by high K ϩ levels. K ϩ (100 mM) was perfused into the striatum through a dialysis probe for the time indicated by the square at 3-4 months. The results are expressed as mean Ϯ SEM (n ϭ 4, interaction of the genotype and time for serotonin release that was stimulated by high K ϩ levels, F (8,48) ϭ 5.399; *p Ͻ 0.001, repeated two-way ANOVA).
orator was used to concentrate the sample and the phosphopeptides were analyzed by LC/MS/MS.
Statistical analysis. The data are presented as mean Ϯ SEM and were analyzed with unpaired t tests, one-way ANOVA with a post hoc Dunnett's test, or a repeated two-way ANOVA. The statistical analyses were performed with the Statview 5.0J software package (SAS Institute). p-values of 5% or less were considered statistically significant.
Results
PKC␥ KO animals exhibited parkinsonian symptoms, including DA release impairment in the striatum AS/AGU rats show altered behaviors (Craig et al., 2001) , DA release impairment, and the pathology of the nigrostriatal system resembles the pathology observed in human patients with parkinsonian syndrome (Campbell et al., 1996; . AS/AGU rats have a spontaneously occurring mutation that changes the CAG (Glu281) codon to a TAG (stop codon) in PKC␥, and the putatively truncated PKC␥, if produced, will terminate at the fifth residue from the C terminus of the last strand of the ␤-sheet structure of the C2 domain (Fig. 1A) . The truncated protein may result in a severe or complete loss of the kinase function of PKC␥, although it has not yet been clarified whether the truncated protein is expressed in AS/AGU rats. Although both anti-PKC␥ (N terminal) Ab and anti-PKC␥ (C2-domain) Ab detected an 80 kDa single band in AS rats, no band was detected in the AS/AGU rats (Fig. 1B) . These findings indicated that PKC␥ was not expressed in AS/AGU rats, suggesting the hypothesis that PKC␥ KO mice show similar symptoms as those observed in AS/AGU rats. We first confirmed that our PKC␥ KO mice did not express PKC␥, whereas the expression levels of other members of cPKCs were unaltered (Fig. 1C) . To determine the effects of the PKC␥ KO on DA release in the striatum, we performed in vivo microdialysis in the striatum. The basal line extracellular levels of DA in the striatum did not differ significantly between the PKC␥ WT and KO mice. After treatment with high levels of K ϩ (Fig. 1D ) and methamphetamine (METH; Fig. 1E ), the increase in DA release in the WT was significantly larger than that in the KO 3-4 months after birth. Although high K ϩ levels induced DA release is mediated by exocytosis and not by DAT, PKC induces DAT endocytosis (Daniels and Amara, 1999), which may decrease the extracellular DA levels by increasing Phosphopeptides with a WT/KO ratio Ͼ1.0 are listed. The numbers of phosphorylation sites are based on the results of mice in PhosphoSitePlus (www.phosphosite.org). S and T are the identified phosphorylation sites. Number of phosphopeptides means the total numbers of the phosphopeptides in each group (n ϭ 4). Highest or lowest peptide score means the highest or lowest peptide score in each group (n ϭ 4). Peptides that were not detected are shown as Ϫ.
DAT activity in PKC␥ KO mice striatum. To evaluate the DAT activity in PKC␥ KO mice, we performed the no-net-flux microdialysis experiment. The slope (extraction fraction) is the measure of the activity of DAT in vivo. Fig. 1G shows decreased DAT activity in the striatum of PKC␥ KO mice, suggesting that PKC␥ KO mice tend to have increased rather than decreased extracellular DA levels compared with WT mice (Fig. 1F ) . Consistent with our results, the increase in the serotonin release stimulated by high K ϩ levels in WT was also significantly larger than that of the KO (Fig. 1G) , as described previously in AS/AGU rats (AlFayez et al., 2005) . Because we had preliminary data that suggested slight loss of DAergic neurons in 12-month-old, but not 3-or 6-month-old, PKC␥ KO mice, there was a possibility that the decrease in DA release in PKC␥ KO mice was due to the decrease in DA in the striatum. We measured DA and its metabolites using HPLC in the striatum. No difference in DA or DA metabolite levels in the striatum was observed between PKC␥ KO mice and WT mice at 3, 6, and 12 months ( Table 1 ), suggesting that DA release disorder was from the exocytotic machinery disorder instead of the lack of the DAergic neurons in the nigrostriatum system. These results suggested that the PKC␥ KO mice would show similar parkinsonian symptoms as those observed in the AS/AGU rats. From the analysis of the PKC␥ KO mice and AS/ AGU rats, we concluded that PKC␥ KO animals could be used as a practical model of parkinsonian syndrome.
Phosphoproteome analysis identified 10 phosphoproteins, including ␤PIX, with a PKC-phosphorylation motif
We hypothesized that a loss or decrease of PKC␥-mediated phosphorylation in the nigrostriatal system results in DA release im- The in vitro phosphorylation of ␤2PIX was also performed in the presence of GFX. The phosphorylated proteins were detected by autoradiography and the levels of protein expression were determined by Western blotting with an anti-FLAG antibody. The numbers show the relative phosphorylation levels that were normalized to PKC␥ stimulation as 1.00 (n ϭ 3). B, In-cell phosphorylation of ␤2PIX. HEK293 cells expressing FLAG-tagged ␤2PIX and GFP-tagged PKC␥ were stimulated with 1 M 12-O-TPA for 20 min in the presence or absence of 1 M GFX or 1 M Gö6976. FLAG-tagged ␤2PIX proteins were purified with anti-FLAG agarose resin. Phosphorylated proteins were detected by an immunoblot analysis with an anti-pSer PKC motif antibody. Protein expression was determined by Western blotting with an anti-FLAG antibody. The average relative phosphorylation levels for each experimental condition were normalized to the prestimulation signal set as 1.00 (n ϭ 5). C, PC12 cells expressing FLAG-tagged ␤2PIX were incubated with 32 P monosodium phosphate and stimulated with 1 M 12-O-TPA in the absence or presence of 1 M GFX. FLAG-tagged ␤2PIX proteins were purified with anti-FLAG agarose resin. Phosphorylated proteins were detected by autoradiography, and protein expression was determined by immunoblots with an anti-FLAG antibody. D, The same amount of samples of total fraction and the P2 synaptosomal fraction were immunoblotted by anti-PSD95 antibody as a postsynaptic marker, anti-VMAT2 antibody as a presynaptic marker, and anti-PKC␥ antibody. E, the P2 synaptosomal fraction was stimulated with 2 M 12-O-TPA in the absence or presence of 2 M GFX. ␤PIX proteins were purified with anti-␤PIX antibody. Phosphorylated proteins were detected by phospho-Abs. The numbers show the relative phosphorylation levels that were normalized to pretreatment as 1.00 (n ϭ 3).
pairment. To identify the substrates for PKC␥, we performed a phosphoproteome analysis using HAMMOC methods (Kyono et al., 2008;  Fig. 2A ). Among the phosphopeptides in the WT group, we chose the proteins that may have a relationship to exocytosis and then calculated the WT/KO ratio of the average ion intensity. The average ion intensity ratio of the phosphopeptides that included the PKC phosphorylation motif are shown in Table 2 . Among these 10 candidates, we focused on ␤PIX (Fig.  2B) , even when the degree of the phosphorylation decrease was small, because it is expressed in DAergic neurons in the SNpc (http://www.informatics.jax.org/assay/MGI:4944920) and has been reported to play important roles in the machinery of exocytosis (Audebert et al., 2004; Momboisse et al., 2009) . In the present phosphoproteome analysis, phosphorylation of Ser340 in ␤2PIX was detected. The ␤PIX family consists of two splicing forms, ␤1 and ␤2; the difference between ␤1 and ␤2 PIX exists in the C terminus (Fig. 2C) . Although both ␤1 and ␤2 contain Ser340, ␤2PIX is the predominant form in the CNS (Koh et al., 2001 ). Therefore, ␤2PIX was used in the present study. , PS, and DO. The phosphorylated proteins were separated by SDS-PAGE and detected by autoradiography (top). The protein levels of the recombinant ␤2PIX protein regions were detected by Western blotting (bottom). The arrowheads on the top indicate the autoradiography and those on the bottom indicate the total protein for each domain. B, In vitro phosphorylation of the ␤2PIX SH3, DH, PH, and ␤2 C terminus regions containing the indicated mutations determined by an in vitro phosphorylation assay that was followed by mass spectrometry and phosphoproteome analysis. Phosphorylation levels were normalized to the WT phosphorylation signal for each domain, which were set to 100%: SH3 (n ϭ 5), DH (n ϭ 4), PH (n ϭ 5), ␤2 C terminus (n ϭ 3); The results are expressed as mean Ϯ SEM (*p Ͻ 0.05, unpaired t test). C, Specificity of anti-phospho-Thr76, Ser340, and Ser583 antibodies. The indicated amount of the phospho-peptide (pT76 [VSPKSG(pT)LKSPP], pS340 [SASPRM-(pS)GFIYQ], and pS583 [SLGRRS(pS)LSRLE]) or non-phosphopeptide was dotted on the PVDF membrane. Immunostaining was performed using purified anti-pT76, pS340, and pS583 antibodies. D, In vitro phosphorylation assay of full-length ␤2PIX. GST-tagged full-length ␤2PIX was expressed in E. coli, purified, and incubated with ATP and recombinant PKC␥ in the presence of Ca 2ϩ , PS, and DO. Phosphorylated proteins were separated by SDS-PAGE and detected by an anti-pSer PKC motif antibody, an anti-pT76 antibody, an anti-pS340 antibody, or an anti-pS583 antibody, respectively.
␤PIX is phosphorylated by PKC␥ in vitro, in cells, and in vivo
To determine whether ␤2PIX was phosphorylated by PKC␥, we performed in vitro, in cells, and in vivo phosphorylation experiments. ␤2PIX was phosphorylated by PKC␥ in vitro, whereas the inhibition of PKC activity with GFX abolished the phosphorylation (Fig. 3A) . Next, we investigated whether ␤2PIX was phosphorylated by PKC in cells. Enhanced phosphorylation of FLAG-tagged ␤2PIX extracted from HEK293 cells transfected with FLAG-tagged ␤2PIX and GFP-tagged PKC␥ after treatment with 1 M TPA was observed with an anti-Ser PKC motif Ab (Fig. 3B) . Furthermore, the TPAinduced phosphorylation of ␤2PIX in cells was reduced by the PKC inhibitors Gö6976 and GFX (Fig. 3B) . These results were further confirmed in PC12 cells (Fig. 3C ) and in the P2 synaptosomal fraction of the mouse brain (Fig. 3D) . Collectively, these results showed that ␤2PIX was phosphorylated by Ca 2ϩ -dependent PKC in vitro, in cells, and in vivo.
PKC␥ phosphorylates Thr76 in SH3, Ser340 in PH, and
Ser583 in the C terminus of ␤2PIX in vitro ␤2PIX consists of the following four regions: SH3 (1-92 aa), DH (93-274 aa), PH (275-400 aa), and the C terminus (401-625 aa). Because each region of ␤2PIX contains one or more predicted PKC phosphorylation sites, we performed an MS analysis combined with an in vitro phosphorylation assay using full-length GST-tagged ␤2PIX for screening the phosphorylation sites by PKC␥. The in vitro PKC assay, followed by the MS analysis, revealed the phosphorylation of Thr76, Ser215, and Ser583 in addition to that of Ser340, which was revealed by the phosphoproteome analysis of PKC␥ KO mice (Fig. 2C) . Thr76, Ser215, and Ser340 are common sites in both ␤1 and ␤2PIX. However, Ser583 is found only in ␤2PIX. To examine the PKC␥-mediated phosphorylation of these sites, recombinant proteins were used in in vitro phosphorylation assays. Importantly, all domains of ␤2PIX were phosphorylated by PKC␥ in vitro, but the SH3 and C-terminal domains were phosphorylated much more strongly than the DH and PH domains (Fig. 4A) . For the next step, we generated recombinant mutant proteins in which each Ser or Thr residue was replaced with Ala (Thr76Ala in SH3, Ser215Ala in DH, Ser340Ala in PH, and Ser583Ala in the C terminus) and examined which Ser/Thr residues of Thr76, Ser215, Ser340, or Ser583 could be phosphorylated by PKC␥ in vitro. We observed that the Thr76Ala and Ser583Ala mutant proteins exhibited impaired phosphorylation of the SH3 and C-terminal domains (Fig. 4B) . The Ser340Ala in the PH domain showed a moderately reduced phosphorylation. The Ser215Ala showed no significant reduction of phosphorylation in the DH domain. These findings suggested that Thr76, Ser340, and Ser583, but not Ser215, are PKC␥ phosphorylation sites in vitro.
cPKC phosphorylates ␤2PIX Ser340 and Ser583 in cells
To further confirm that ␤2PIX is phosphorylated by cPKC in cells, we produced Abs that specifically recognized phosphorylated Thr76, Ser340, and Ser583 (Fig. 4C) . The purified full-length ␤2PIX was phosphorylated by recombinant PKC␥ in vitro and then applied to SDS-PAGE, which was followed by Western blotting with the anti-pT76, anti-pS340, and anti-pS583 Abs. The ␤2PIX that was phosphorylated by PKC␥ was detected by anti-pT76 and anti-pS583, but not the anti-pS340 Ab (Fig.  4D) , suggesting that Ser340 was not a direct PKC phosphorylation site. Next, we investigated whether ␤2PIX was phosphorylated at Thr76, Ser340, and Ser583 in cells. Figure 5 shows that Ser340 and Ser583, but not Thr76, were phosphorylated in TPAtreated HEK293 cells. Moreover, the PKC-dependent phosphorylation of Ser340 and Ser583 was confirmed with the PKC inhibitors Gö6976 and GFX (Fig. 5) . These findings suggested that Ser340 and Ser583 were phosphorylated by cPKC in cells. It is noteworthy that Ser583 was phosphorylated directly, whereas Ser340 was phosphorylated indirectly by PKC␥.
Involvement of cPKC in the regulation of DA release
A 3 H-DA release assay in PC12 cells, a cell line in a DAergic neuronal model, was used to study the functional role of PKC and ␤PIX in the regulation of DA release. PC12 cells expressed endogenous ␤PIXs and cPKCs, including PKC␥ (Fig. 6A) . To determine the degree of DA release stimulated by K ϩ , PC12 cells were stimulated with various K ϩ concentrations and the DA release was increased in a K ϩ concentration-dependent manner (Fig.  6B) . The functional role of cPKC in the regulation of K ϩ -induced DA release was monitored with Gö6976 and GFX. These PKC inhibitors significantly decreased the high K ϩ -stimulated DA release (Fig. 6C) . It is noted that there were no differences of 3 H-DA uptake into the PC12 cells between the control and PKC inhibitor groups (Fig. 6 D, E) . Gö6976 and GFX also significantly suppressed the TPA-stimulated DA release (Fig. 6F ) . The activation of PKC␥ after K ϩ -induced depolarization was confirmed by monitoring the translocation of GFP-tagged PKC␥ from the cytosol to the plasma membrane in PC12 cells (Fig. 7A) . These Figure 5 . PKC mediates the phosphorylation of full-length ␤2PIX at Ser340 and Ser583 in cells. HEK293 cells transfected with FLAG-tagged WT ␤2PIX and GFP-tagged PKC␥ were stimulated with 1 M TPA in the presence or absence of 1 M GFX, which is a pan-PKC inhibitor, or Gö6976, which is a cPKC inhibitor. FLAG-tagged ␤2PIX was precipitated and separated by SDS-PAGE. The total amounts of protein were determined by immunoblot analyses with an anti-FLAG antibody. GFP-tagged PKC␥ or ␤ actin was detected by anti-GFP or anti-␤-actin antibodies. The phosphorylation levels of the FLAG-tagged ␤2PIX proteins that were determined with an anti-pT76 antibody (A; n ϭ 2), an anti-pS340 (B; n ϭ 4), or an anti-pS583 (C; n ϭ 4) antibody were normalized to the phosphorylation levels of the WT. The numbers show the average relative phosphorylation levels that were normalized to prestimulation levels set as 1.00.
results suggested that cPKC plays a crucial role in K ϩ -induced DA release machinery in PC12 cells.
␤PIX KD suppressed DA release Because ␤PIX is able to stimulate growth hormone secretion from PC12 cells (Momboisse et al., 2009; Momboisse et al., 2010) , we investigated the possible relationship between ␤PIX and DA release. KD of ␤PIX in PC12 cells by shRNA (sh369) resulted in a significant inhibition of K ϩ -evoked DA secretion from PC12 cells (Fig. 7B) . A similar significant reduction in DA release was reproduced with synthetic ␤PIX siRNA (Fig. 7C) . These results were consistent with the idea that ␤PIX is an important element of the DA exocytotic machinery.
PKC-mediated phosphorylation of ␤2PIX at Ser340 and Ser583 promoted DA release
To determine the role of the PKCmediated phosphorylation of ␤PIX in DA release, we exogenously and simultaneously introduced the shRNA-resistant forms of ␤2PIX mutant, including ␤2PIX Thr76Ala, Ser340Ala, or Ser583Ala mutants and ␤PIX sh369, into PC12 cells. DA release from PC12 cells transfected with sh369 was completely rescued by the reintroduction of WT FLAG-tagged ␤2PIX (Fig. 8A) . These results suggested that ␤2PIX, which is a dominant isoform in the CNS, has important roles in DA release. Moreover, we examined the effects of the ␤2PIX phosphorylation on DA release. ␤2PIX Ser340Ala and Ser583Ala mutants failed to rescue the reduced DA release by ␤PIX sh369, whereas the ␤2PIX Thr76Ala mutant acted similarly to WT ␤2PIX (Fig. 8A) . Together, our results suggested that the PKC-mediated phosphorylation of Ser340 and Ser583 on ␤2PIX positively regulates DA release. Finally, we examined the effects of Cdc42 and Rac1 KD on DA release. When Cdc42 was knocked down, Rac1 was upregulated and vice versa. Therefore, we knocked down both Cdc42 and Rac1. The KD of both Cdc42 and Rac1 in PC12 cells by shRNAs resulted in a significant inhibition of K ϩ -evoked DA release from PC12 cells (Fig. 8B ).
Discussion
In this study, we revealed that AS/AGU rats did not express fulllength PKC␥ or the truncated form of PKC␥, indicating that a loss, and not a gain, of function is the cause of the parkinsonian symptoms exhibited by AS/AGU rats. In agreement with these findings, we demonstrated decreased DA release stimulated by high levels of K ϩ and METH in the striatum. It is noteworthy that altered DA release is the predominant characteristic of parkinsonian symptoms in PKC␥ KO mice rather than loss of DAergic neurons in the SNpc. We propose that PKC␥ KO animals are useful models for the study of parkinsonian syndrome because PKC␥ KO mice and AS/AGU rats have damage not only in the DAergic system, but also in the serotonergic system (Al-Fayez et al., 2005) , as has been observed in patients with sporadic Parkinson's disease. Furthermore, the use of the PKC␥ KO mouse model has an advantage because it is possible to perform gene manipulations in them, such as PKC␥ rescue, compared with the AS/AGU rats.
Although it is generally accepted that DA release in the striatum induced by high K ϩ levels is mediated by exocytosis and not by DAT, PKC was reported to induce DAT endocytosis (Daniels and Amara, 1999) , which, by altering DA reuptake, can change the amplitude of K ϩ -induced DA release as measured by microdialysis. We have ruled out this possibility because DAT activity was instead decreased in PKC␥ KO mice (Fig. 1F ) . Moreover, 3 H-DA uptake does not differ between the control and PKC inhibitors in PC12 cells (Fig. 6 D, E) . These results suggested that the reduced K ϩ -induced DA release was not through the change of the DAT endocytosis by the PKC␥ KO. There are also reports that activation of PKC induces DAT-mediated DA reverse transport (Kantor and Gnegy, 1998; Cowell et al., 2000) . Although . C, Amounts of DA release that were stimulated in response to 100 mM K ϩ with 1 M GFX or 1 M Gö6976 were measured in PC12 cells (n ϭ 3; *p Ͻ 0.05, unpaired t test). DA release levels were normalized to the levels released in response to 100 mM K ϩ , which were set to 100%. The results are expressed as mean Ϯ SEM (n ϭ 3-5). D, E, Uptake of 3 H-DA into PC12 cells with or without GFX and Gö6976 were measured. The results are expressed as mean Ϯ SEM (n ϭ 3). F, TPA stimulated DA release in PC12 cells. DA release in PC12 cells was measured with 1 M TPA in the absence or presence of 1 M GFX. DA release levels were normalized to that of 1 M TPA stimulation, which was set to 100%. The results are expressed as mean Ϯ SEM (n ϭ 3, *p Ͻ 0.01, unpaired t test).
these studies focused more on PKC␤ than on PKC␥, our study showed that PKC␥ also play important roles for DAT-mediated DA reverse transport (Fig. 1F ) , suggesting that PKC␥ play roles for both K ϩ -mediated DA release and DAT-mediated DA reverse transport. Therefore, PKC␥ KO resulted in decreased DAT activity, including uptaking DA and DA reverse transport through DAT. The decreased level of K ϩ -induced DA release in PKC␥ KO mice is probably underestimated: DA release may be more significantly decreased when the disordered DAT activity is normalized.
We identified 10 phosphoproteins that were decreased in PKC␥ KO mice under the hypothesis that decreased levels of phosphorylated substrates of PKC␥ in the nigrostriatal system lead to impairments in DA release. Our results indicated that ␤PIX was one of the pivotal targets of PKC␥ or cPKC in enhancing Ca 2ϩ -evoked DA release based on the following several lines Al-Fayez et al., 2005; Kawasaki et al., 2010; . Our data suggest that PKC␥ has important roles in DA release in mice.
In neurons, Ca 2ϩ entry triggers exocytosis, suggesting that certain Ca 2ϩ sensors may be necessary for Ca 2ϩ -dependent exocytosis. Candidates for Ca 2ϩ sensors include molecules that possess EF hand motifs or C2 domains, which were first defined in cPKC, and annexin family proteins, as has been reported previously (Burgoyne and Morgan, 1998) . PKC has been reported to modify exocytosis in the steps both before and after docking to the plasma membrane through the following mechanisms: (1) increased vesicle recruitment into the readily releasable pool (Gillis et al., 1996; Stevens and Sullivan, 1998) , (2) acceleration of fusion pore expansion (Scepek et al., 1998) , and (3) changes in the kinetics of exocytosis (Graham et al., 2002) . However, ␤PIX is related to the exocytosis step after docking (Momboisse et al., 2009; Momboisse et al., 2010) . The cPKC-␤PIX-Cdc42/Rac1 axis possibly has important roles in DA release in the step after docking through the ␤PIX phosphorylation by cPKC.
How can ␤PIX regulate DA release through the phosphorylation at Ser340 or Ser583? Previous reports have revealed that ␤PIX phosphorylation results in ␤PIX translocation to the membrane and the subsequent activation of Rac1 and/or Cdc42. In PC12 cells, basic fibroblast growth factor induces the phosphorylation of ␤PIX at Ser525 and Thr526, resulting in neurite outgrowth by the activation of Rac1 through the translocation of the ␤PIX complex at neuronal growth cones (Shin et al., 2002; Shin et al., 2006) . In human mesangial cells, endothelin-1 and cAMP inducers cause the PKA-dependent phosphorylation of ␤PIX at Ser516 and Thr526, resulting in cytoskeletal rearrangement by the activation of Cdc42 through ␤PIX translocation (Chahdi et al., 2005) . Therefore, ␤PIX may be differently phosphorylated in response to various stimuli and this may result in its stimulus-dependent specific targeting and Cdc42/Rac1 activation at the targeted sites. We have demonstrated for the first time that Ser583 is a PKC␥ or cPKC phosphorylation site. Ser583 and the previously reported sites Ser516, Ser525, and Thr526 are all located in the C-terminal domain of ␤PIX and may have similar functions for the translocation and subsequent activation of Cdc42/Rac1. Phosphorylation at Ser340 is located in the PH domain, which interacts with phosphatidylinositol lipids within biological membranes (Wang and Shaw, 1995) and may also play important roles in the membrane targeting of ␤PIX. In fact, the PH domain has been reported to interact with PKC (Yao et al., 1994) and Cdc42 (Rossman et al., 2002) and it has been implicated in the regulation of the GEF activity of SOS (Ras-GEF; Karlovich et al., 1995) and p140Ras-GRF (Ras and Rac GEF; Buchsbaum et al., 1996) . Therefore, through PH-domain-mediated membrane targeting and interaction, the cPKC-␤PIX-Cdc42/Rac1 axis may act at specific membranes (Chen et al., 1997; Falasca et al., 1998; Maffucci and Falasca, 2001) . Downstream of the ␤PIX phosphorylation, we speculate that Cdc42/Rac1 are the targets of phosphorylated ␤PIX, as suggested in previous studies (Shin et al., 2002; Shin et al., 2004; Chahdi et al., 2005; Shin et al., 2006) . Although we have not proved a direct relationship between phosphorylated ␤PIX and Cdc42/Rac1, we speculate that ␤PIX phosphorylated by PKC␥ regulates Cdc42/Rac1 functions based on our data that the double KD of Cdc42 and Rac1 resulted in decreased DA release (Fig. 8B) .
Although Ser340 is common to both ␤1PIX and ␤2PIX, Ser583 only exists in the unique C terminus of ␤2PIX, which is the neuron-dominant isoform (Koh et al., 2001 ) that emerged from and was conserved after Xenopus laevis (Fig. 9) . Therefore, Ser583 phosphorylation by neuron-specific PKC␥ may have important roles in the modulation of ␤PIX function in the highly developed CNS and highly elaborated function, including DA release. It is also of note that the reported phosphorylation sites at Ser340, Ser516, Ser525, and Thr526 are conserved through evolution. Although we detected the TPA-induced phosphorylation of ␤2PIX in vivo using the synaptosomal P2 fraction of PKC␥ WT mice by pSer PKC motif Ab (Fig. 3D) , we could not show clear TPA-induced phosphorylation at Ser340 and Ser583 in PKC␥ WT using our site-specific phospho-Abs for pS340 and pS583, likely due to the sensitivity of anti-pS340 and pS583 Abs.
In the present study, we have demonstrated that PKC␥ KO mice can be a useful model of parkinsonian syndrome. In addition, we found for the first time that DA release was positively regulated by the PKC-mediated direct phosphorylation of ␤PIX at Ser583 and indirect phosphorylation at Ser340. The phospho- Figure 8 . Phosphorylation of ␤2 PIX at Ser340 and Ser583 promotes DA release. A, DA release was measured in PC12 cells that were transfected with sh␤PIX and ␤2PIX (WT and Ser-Ala mutants) with shRNA-resistant sequences. The levels of endogenous ␤1, ␤2PIX, and exogenous ␤2PIX were confirmed. Comparable levels of all ectopically expressed ␤2PIX proteins were confirmed by Western blot analyses. The results are expressed as mean Ϯ SEM (n ϭ 3-6, *p Ͻ 0.05, one-way ANOVA with post hoc Dunnett's test). B, DA release was measured in PC12 cells that were transfected with shRNA for both Cdc42 and Rac1 and sh Control, which was used as a negative control. The results are expressed as mean Ϯ SEM (n ϭ 3, *p Ͻ 0.01, unpaired t test). Figure 9 . Schematic comparisons of Ser340 and Ser583 through evolution. Ser340 and Ser583 are evolutionally conserved in many species. It is noted that ␤2PIX emerged from X. laevis, although ␤1PIX is expressed in Drosophila melanogaster. Ser516, Ser525, and Thr526, as reported previously, are also conserved in many species.
